Three currently circulating omicron subvariants of SARS-CoV-2—including two that currently make up almost 50% of reported COVID-19 infections in the U.S.—are better at evading vaccine- and infection-generated neutralizing antibodies than earlier versions of omicron, suggests new research published in Cell Host & Microbe.